Compare 10X Genomics Inc (TXG) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs 22nd Century Group Inc — how do they compare? 10X Genomics Inc trades at $46.82 (market cap $5.48B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: 10X Genomics Inc is far larger — about 3677.9× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| TXG | XXII | |
|---|---|---|
Market Cap | $5.48B | $1.49M |
Sector | Health | Technology |
52-Week High | $45.80 | $1.07K |
52-Week Low | $11.34 | $3.90 |
Enterprise Value | $5.02B | -$6.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $4.32, down 0.23% with bearish technical signals. The company shows negative profitability with -65.76% net income margin and -130.19% ROE, though valuation ratios appear low with P/S of 0.03. Recent corporate actions include a 20:1 reverse stock split in June 2026. The company is expanding VLN product distribution in key markets including California and New York, supported by positive FDA regulatory developments.
While analyst consensus is 75% buy-rated, fundamental challenges persist with consistent revenue declines and negative cash flow from operations. Investment opportunity lies in successful VLN brand expansion and regulatory approvals, but risks include ongoing losses, competitive tobacco market pressures, and execution uncertainty in scaling reduced-nicotine products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
